Literature DB >> 32325249

Exposure to low dose ZnO nanoparticles induces hyperproliferation and malignant transformation through activating the CXCR2/NF-κB/STAT3/ERK and AKT pathways in colonic mucosal cells.

Jian Meng1, Xiaoling Zhou1, Juan Yang1, Xianjun Qu2, Shuxiang Cui3.   

Abstract

As ZnO nanoparticles have been applied in many fields, their biological risks on human health, of course, are worthy of our attention. Whether ZnO NPs have the risk and how colonic cells respond to the invaded ZnO NPs are still unknown. Herein, we evaluated the biological effects of ZnO NPs on colonic mucosal cells by in vitro and in vivo methods. IMCE cells, with APC mutation but phenotypically normal, demonstrated hyperproliferation through activating the CXCR2/NF-κB/STAT3/ERK and AKT pathways when exposed to ZnO NPs for 24 h. Long-term exposure of ZnO NPs resulted in the malignant transformation of IMCE cells, showing the morphological changes, anchorage-independent cell growth ability. Importantly, IMCE cells exposed to ZnO NPs subcutaneously grew and induced tumorigenesis in nude mice. In conclusion, exposure of ZnO NPs could induce malignant transformation of colonic mucosal cells through the CXCR2/NF-κB/STAT3/ERK and AKT pathways. We suggest that it was necessary to consider using the precautionary principle for gastrointestinal contact nanomaterials.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hyperproliferation; Long-term exposures; Low-dose exposures; Malignant transformation; ZnO nanoparticle

Mesh:

Substances:

Year:  2020        PMID: 32325249     DOI: 10.1016/j.envpol.2020.114578

Source DB:  PubMed          Journal:  Environ Pollut        ISSN: 0269-7491            Impact factor:   8.071


  1 in total

1.  Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses.

Authors:  Sui-Yuan Chang; Kuo-Yen Huang; Tai-Ling Chao; Han-Chieh Kao; Yu-Hao Pang; Lin Lu; Chun-Lun Chiu; Hsin-Chang Huang; Ting-Jen Rachel Cheng; Jim-Min Fang; Pan-Chyr Yang
Journal:  Sci Rep       Date:  2021-04-22       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.